Madras High Court has ruled against Novartis appeal which challenged the constitutional validity of section 3(d) of the Patents Act 1970 which according to Novartis excludes ‘incremental innovation’ from patent protection and denies patents for modifications of known medicines. Ranjit Shahani, Managing Director Novartis India said that Novartis is likely not to appeal to the Supreme Court.